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ARTICLE INFO  ABSTRACT  
Hyperthyroid disease requires continuous treatment with not cheap medical costs. 
For JKN participants, the cost of treating hyperthyroidism has been fully covered 
by BPJS through the INA-CBG package. However, there is often a mismatch between 
the INA-CBG package and the real hospital costs thus causing losses for the hospital. 
This research is a comparative study with a hospital perspective and the purpose 
of this study is analyze difference between direct medical cost of hospitals and INA-
CBG package for the treatment of JKN outpatient hyperthyroidism patient in 
Hasanuddin University Hospital (RSUH) Makassar using data from January 2017 to 
December 2018. Data collection was carried out by retrospective observational and 
data analysis using statistical non-parametric tests. The results showed that INA-
CBG package cannot cover all components of the costs of treating hyperthyroid 
disease. The laboratory cost has a proportion of 83% of the total medical cost, 
which is an average of IDR 465.683,70 every patient. Meanwhile, the INA-CBG rate 
with code Q-5-44-0 only covers medical expenses of IDR 185.500 every patient. The 
conclusion of this study shows that there is a negative difference (-) between the 
real cost of the hospital and the INA-CBG rate, which is IDR 34.406.900,00 and an 
average of IDR 373.988.04 every patient. The recommendation is related to 
adjustment of the INA-CBG rate to cover the riil costs. 
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Penyakit hipertiroid memerlukan pengobatan secara berkesinambungan dengan 
biaya pengobatan yang tidak murah. Bagi peserta JKN biaya pengobatan penyakit 
hipertiroid telah di cover sepenuhnya oleh BPJS melalui paket INA-CBG. Namun, 
sering terdapat ketidak cocokan antara paket INA-CBG dengan biaya riil rumah 
sakit. Sehingga, menimbulkan kerugian bagi rumah sakit. Penelitian ini merupakan 
studi perbandingan dengan perspektif rumah sakit dan tujuan dari penelitian ini 
adalah menganalisis perbedaan antara biaya riil rumah sakit dengan tarif paket 
INA-CBG pada pasien hipertiroid rawat jalan peserta JKN di Rumah Sakit Universitas 
Hasanuddin (RSUH) Makassar menggunakan data periode Januari 2017 sampai 
dengan Desember 2018. Pengumpulan data dilakukan secara observasional 
retrospektif dan analisis data menggunakan statistic non parametric test. Hasil 
penelitian menunjukkan bahwa tarif paket INA-CBG tidak dapat menutupi semua 
komponen biaya pengobatan pada penyakit hipertiroid. Komponen biaya 
laboratorium memiliki proporsi sebesar 83% dari total biaya pengobatan yaitu rata-
rata sebesar Rp. 465.683,70 per pasien. Sedangkan, tarif paket INA-CBG dengan kode 
Q-5-44-0 hanya menanggung biaya pengobatan sebesar Rp. 185.500 per pasien. 
Kesimpulan dari penelitian ini menunjukkan adanya selisih negatif (-) antara biaya 
riil rumah sakit dengan tarif paket INA-CBG yaitu sebesar Rp.34.406.900,00 dan rata-
rata sebesar Rp.373.988,04 per pasien. Sehingga, memerlukan adanya rekomendasi 
penyesuaian tarif INA-CBG. 





Hyperthyroid disease is an abnormalities 
dysfunction of the thyroid gland, and this disease 
is found in many societies. The prevalence of 
hyperthyroid disease in Europe is 0,8% and in 
the United States is 1,3%.1 Meanwhile, the 
prevalence of hypothyroidism in Indonesia is 
0,4% and in the South of Sulawesi is 0,5%.2,3 
Hyperthyroidism is a condition when the 
thyroid gland is hyperactive in producing 
thyroid hormones so that the thyroid hormone 
levels in the blood increase and are above 
normal limits.4  
Treatment of hyperthyroid disease must 
be carried out continuously with antithyroid 
drug therapy for at least 1-2 years so that it 
requires expensive medical costs, and causing 
the low level of public awareness to check 
themselves and take medication when expe-
riencing clinical symptoms of hyperthyroidism 
are social and economic factors.2,5 The untreated 
hyperthyroid disease can lead to serious clinical 
complications and disadvantage patients so, 
increasing health care costs.6,7 
However, for JKN participants, all costs 
for treating hyperthyroidism are borne by BPJS. 
JKN stands for National Health Insurance which 
functions to meet the needs of proper health for 
the community.8 The implementation of claim 
payments for treatment provided by the hospital 
as an advanced health facility uses the 
Indonesian Case Based Groups (INA-CBG) 
prospective payment package system.9 Deter-
mination of the hospital real cost rate serves to 
minimize losses from each cost of activities and 
services which include operating costs, 
maintenance, development and improve-ment 
of the quality of hospital services.10 In addition, 
the determination of the hospital service tariff 
must be in line with the increase in the value of 
hospital services and the ability of the 
community to pay for each of these services.10 
Since the JKN system was imple-mented in 
several hospitals there has often been a 
mismatch between the real hospital costs and 
the INA-CBG package,10 so it is necessary to do 
research on the analysis of the difference in real 
hospital costs and INA-CBG on hyperthyroidism. 
This research is an extension of the 
research that has been conducted by Dian Ayu 
Juwita, Suhatri and Risa Hestia, in two things, 
that is the differences in the focus of observation 
and differences in research methods. This study 
has the advantage of the method used in 
analyzing direct medical cost comparisons with 
an INA-CBG package from BPJS. While the focus 
of observation focuses on the component of 
outpatient hyperthyroid treatment costs at the 
Hasanuddin University Hospital (RSUH). 
Because, from the medical record data of 
outpatient RSUH it is known that the total of 
patients with a diagnosis of hyperthyroidism is 
increasing every year.11 The use of new methods 
that support the comparison of recent costs in 
this study. The purpose of this study was to 
analyze the real hospital costs with the INA-CBG 
package for outpatient hyperthyroidism par-
ticipating in JKN at RSUH.
 




MATERIAL AND METHOD 
This study used a retrospective 
observational with a hospital perspective and 
used two types of data that is, qualitative data 
and quantitative data. Qualitative data are 
descriptive data obtained from Hospital medical 
records, quantitative data is the form of numbers 
or nominal information on the results of tracing, 
medical costs and the INA-CBG package for 
outpatient hyperthyroid patients JKN parti-
cipant using data from January 2017 to 
December 2018. Direct medical costs or real 
hospital costs are costs incurred in accordance 
with valid proof of expenditure as compensation 
received by the hospital for services provided to 
patients.12 Meanwhile, the INA-CBG package is a 
system of claim fee packages by BPJS which 
functions as hospital claim costs based on 
grouping of diseases and therapies that have 
similarities.12 Cost data are obtained from the 
Hospital Management Information System (SIM-
RS) in the casemix unit, the research was 
conducted in July 2019-June 2020 and has 
obtained an ethical approval recommendation 
from the Hasanuddin University Medical Faculty 
(FKUH) with a number 6/UN4.6.4.5.31/PP36/ 
2019.  
The population in this study was 
outpatient hyperthyroidism with a total 
population of 1,139 and the sampling technique 
used was purposive sampling.13 The total of 
samples in this study was 92 respondents who 
were determined based on the results of 
calculations using the Yamane formula.13 The 
data were collected by tracing secondary data in 
the form of medical records and data on medical 
bills through SIM-RS in the casemix unit and 
outpatient pharmacy installation of RSUH. The 
collected data is then processed with statistical 
software in the form of Statistical Package for 
Social Sciences (SPSS) version 23 that is, using 
univariate data analysis and descriptive 
statistics to describe the characteristics and 
components of the real hospital costs and test 
the difference between two or more groups of 
variables using a non parametric test that is, 
mann whitney u test and kruskall wallis.13 The 
data analysis to see a comparison between real 
hospital costs and INA-CBG rates analyzed using 
the mann whitney u test. 
RESULTS  
Analysis of basic characteristics was 
carried out on each research respondent 
grouped by gender, age, education level and type 
of worker. The results of the characteristics 
respondent’s analysis are presented in Table 1. 
The distribution of the basic characteristics of 
research respondents based on the female 
gender group was more than that of male 
respondent that is, as much 77 patients. The 
highest distribution of characteristics in the age 
group of 26-35 years and the lowest in the 56-65 
years age group with 11 patients. The 
distribution of the characteristics of the highest 
education level that is, the Senior High School 
group of 45 patients and the education level 
group with the least total of respondents of the 
Junior High School group with 8 patients. The 
distribution of the characteristics of the types of 
workers was mostly in the unemployed group as 




many as 58 patients and for the not working 
group most of the housewives (IRT) were 34 
patients (Table 1). 
The results of the analysis of the 
components of treatment costs in Table 2, it can 
be concluded that, of 92 outpatient hyperthyroid 
patients who completed one treatment cycle 
included administration costs, doctor consul-
tation costs, laboratory examination costs and 
drug costs. The cost component that has the 
largest cost of the total real hospital costs, 
sequentially, is the laboratory cost of 83% or an 
average of IDR 465.683,70 every patient, doctor 
consultation fee 12% or an average of IDR 
69.347,83 every patient. Patients, the cost of 
drugs is 3% or an average of IDR 14.347,83 
every patient and 2% administration fee with an 
average of IDR. 10.108,70 every patient (Table 
2).  
The results of statistical analysis in Table 
3. Can be concluded that the INA-CBG package 
cannot cover all components of the costs 
incurred by hyperthyroid patients, causing the 
difference (-) IDR 373.988,04 every patient. 
 
Source: Secondary Data of the Hospital SIM, 2017-2018 
Table 2. Component of Real Cost in Hyperthyroid Patients 
Cost component Total (IDR) Average (IDR) Proportion (%) St. Dev (IDR) 
Administrative Costs 930.000,00 10.108,70 2 3550,1324 
Doctor Consultation Costs 6.380.000,00 69.347,83 12 25615,6866 
Laboratory Costs 42.842.900,00 465.683,70 83 98125,5602 
Drug Costs 1.320.000,00 14.347,83 3 9605,3268 
Source: Secondary Data of the Hospital SIM, 2017-2018 
Table 3. Difference between Real Hospital Costs and INA-CBG Package Rates 
Total 
Respondents 









92 51.472.900,00 17.066.000,00 0,000 (-) 34.406.900,00 (-) 373.988,04 
Source: Secondary Data of the Hospital SIM, 2017-2018
Table 1. Characteristics of Respondents 
Characteristics n = 92 Total Cost (IDR) Average Cost (IDR) St. Dev (IDR) p 
Gender     
0,173 Male 15 7.926.600,00 528.440,00 87699,1676 
Female 77 43.546.300,00 565.536,36 102447,77 
Age (Years)     
0,603 
17-25  18 10.118.100,00 562.116,67 69701,9896 
26-35  26 14.353.400,00 552.053,85 108629,794 
36-45 21 12.017.700,00 572.271,43 114699,273 
46-55  16 8.523.100,00 532.693,75 110283,172 
56-65  11 6.460.600,00 587.327,27 86285,3416 
Level of Education      
0,555 
Elementary School 14 8.138.500,00 581.321,43 97915,9937 
Junior High School 8 4.039.600,00 504.950,00 99806,9852 
Senior High School 45 25.285.100,00 561.891,11 111646,817 
University 25 14.009.700,00 560.388,00 78802,5926 
Type of Workers     
0,547 Working 34 18.475.300,00 543.391,18 94214,0225 
Not Working 58 32.997.600,00 568.924,14 103933,404 





Hyperthyroid disease is a type of 
autoimmune disease caused by an increase in 
the synthesis and secretion of thyroid hormones 
in the thyroid gland so that thyroid hormone 
levels increase in the blood.4 Thyroid hormone 
has an important role in growth, nerve 
development, reproductive system, and regu-
lation of energy metabolism.14 
According to gender of the Hyperthyroid 
outpatient the total of female is bigger than male. 
Hyperthyroid disease is diagnosed both of male 
and female but, in the female more risk to suffer 
from the Hyperthyroid disease it causes some 
factor and one of them is the effect of estrogen 
hormone. Estrogen hormone increases the level 
of Thyroxine Binding Globulin (TBG) it causes 
the level of T4 and T3 to be increased, that can 
be Hyperthyroid.1,15 While in male, Hyperthyroid 
disease can be affected by unhealthy lifestyle for 
example smoking.2 Average cost incurred by the 
female and male patient did not show significant 
difference. Prevalence of Hyperthyroid disease 
in South Sulawesi is 0,5% and in Indonesia the 
prevalence of population that is diagnosed with 
Hyperthyroid is higher in the female which is 
0,6%.2 Signs and symptoms of Hyperthyroid 
disease are palpitation, exhaustion, the tremor 
of extremities, sleep disturbance anxiety, losing 
weight, high temper intolerance, sweating, 
polydipsia and tachycardia.1 
Base on the age characteristic, age group 
between 26-35 years more than the other age 
groups. Hyperthyroid disease can occur in all 
ages but the risk of Hyperthyroid disease is 
higher in between 20-40 years old because it is 
in a fertile age with high productivity so it raises 
anxiety, stress and depression. Hyperthyroid 
disease has been linked with psychiatric 
morbidity increase, hormone thyroid increase in 
blood (Hyperthyroid) can cause anxiety and 
depression.16 Previous researches have been 
proved that there is impact and significant 
relation between Thyroid Stimulating Hormone 
(TSH) and Thyroid Receptor Antibodies (TRAb) 
of anxiety, stress and depression.16 Besides the 
stress factor, 26-35 years old are a fertile age or 
a reproductive period and in this period 
estrogen hormone will increase thus causing 
enhancement of thyroid hormone production in 
blood (Hyperthyroid).17,18,19 Average medical 
expenses incurred of the respondents with age 
group 56-65 years (elderly) more than the age 
group 26-35 years because, elderly Hyper-
thyroid patients are often accompanied with 
atrial fibrillation disease that can cause heart 
failure disease and stroke. So, the type of 
laboratory tests are more numerous and need 
more costs before starting therapy and after 
giving antithyroid drug therapy.20 In previous 
researches also concluded that there were 5% 
atrial fibrillation cases caused by Hyperthyroid 
disease.20 Hyperthyroid disease in Indonesia is 
more dominant in patients with age range 45-75 
years as much as 0,5%.2 Hyperthyroid disease in 
the elderly is a cause of the reduction function of 
the thyroid gland so, the level of  TSH 
decreased.21  
According to the level of education 
characteristic, it shows that patients in the 
senior high school more than patients in the 




junior high school as much as 45 patients. This 
research is in line with previous research that 
said in senior high school more risk attached 
thyroid disorders than in elementary school and 
junior high school.22 The other research also 
concluded that, Hyperthyroid patients in 
Indonesia with education level D1, D3 and 
bachelor have prevalence as much as 0.5%.2 
Even there is not previous research that proves 
the impact and relation between Hyperthyroid 
patients and education level.22 According to jobs 
characteristics, show that the respondent who 
does not work more than the respondent with a 
job. Characteristics of the not-working patients 
on average are house wife while the working 
patients are civil servants, police, army, private 
employees and self- employed. Hyperthyroid 
disease poses more risk to the house wife 
because the change of estrogen hormone during 
and after pregnancy so it affects the function of 
thyroid.17, 23 Prevalence of Hyperthyroid disease 
patients in Indonesia have higher risk in the non-
working group as much as 0,5% than in the 
working group as much as 0,4%.2 Social and 
economic factors be the one of the cause of the 
lack of awareness and access to check their-self 
determination in the health facility (hospital) 
when they experiencing Hyperthyroid symp-
toms.2 Previous researches conclude that there 
is nothing significant relation between jobs and 
anxiety, as much as 46,7% of house wives 
experiencing anxiety as the outcome of Hyper-
thyroid disease can be lowered with doing 
counseling. Because, when counseling the 
patient can tell or express their emotion, feeling 
and their mind.24 
According to the proportion of the real 
cost components, the component of laboratory 
cost has the biggest proportion than adminis-
tration cost, doctor consultation cost and drugs 
cost is as much as Rp. 42.842.900,00 and average 
of Rp. 465.683,70 for each patient or as much as 
83% from the total real cost of the hospital. 
Hyperthyroid disease is a disease that often 
occurs without realizing it. One of the clinical 
symptoms is the front of the neck enlargement 
and heart palpitations (tachycardia).25,26 Hyper-
thyroid disease only can detected through 
primary laboratory test those are TSHs, FT4 or 
FT3.27 The test of FT4 (Free Thyroxine), TSHs 
(Thyroid Stimulating Hormone serum) and FT3 
(Free Triiodothyronine) are primary laboratory 
test in diagnosis Hyperthyroid disease because, 
the these three test for knowing the level of 
thyroid hormone in blood.5 Beside that, using 
USG Thyroid also for evaluation the condition of 
organs in te thyroid gland.5  
The test of the thyroid gland in blood 
periodically is very needed to monitor the 
therapy result with antithyroid drugs and for 
knowing the level of thyroid hormone in blood.26 
The secondary laboratory test to view the harm 
of the other organ which causes Hyperthyroid 
disease or adverse effect from the use of 
thionamide class (PTU and Methimazole or 
Thiamazole) antithyroid drugs those are liver 
function test, kidney function test and blood test. 
Every laboratory test needs quite an expensive 
cost.5,28  




The use of antithyroid for Hyperthyroid 
disease can be used as the main therapy or the 
therapy before surgery of the thyroid gland 
(radiotherapy).29 Methimazole is the first time 
therapy of Hyperthyroid disease while, 
Prophyltiuracil (PTU) is is the first time therapy 
of Hyperthyroid disease in the early trimester of 
pregnancy.30 Hyperthyroid disease needs 
treatment continuously. But, the use of 
antithyroid drugs on a prolonged basis will 
cause a negative effect on the patient body. 
Methimazole has minor adverse drugs reactions 
like rash, itching of the skin, vertigo and swelling 
of the salivary glands. While, major adverse 
drugs reactions like Thrombocytopenia, 
Agranulocytosis, Carcinogenesis and Hepato-
toxic.31 Propylthiouracil (PTU) has minor nausea 
adverse drugs reaction, like gag and edema. And 
major adverse drugs reaction like agra-
nulocytosis and hepatotoxicity.32 With these 
negative effects, so the cost that needed in the 
laboratory test will increase. Except the primary 
laboratory test, secondary laboratory test is also 
required.  The type of secondary laboratory test 
before and after giving the therapy antithyroid 
which is the test of SGOT (Serum Glutamic 
Oxaloacetic Transaminase), SGPT (Serum 
Glutamic Pyruvic Transaminase), direct bilirubin, 
total bilirubin, automatic routine hematology, 
urine test, urea and creatinine and EKG 
(electrocardiogram).33  
EKG test of the Hyperthyroid patients is 
very important because it very much help in 
diagnosis, prognosis or determination of drugs 
therapy. Hyperthyroid disease has clinic 
symptoms like tachycardia, because the thyroid 
hormone has a role directly or indirectly on the 
cardiovascular system.21,34 Thyroid hormones 
gives electrophysiology and inotropic effects of 
heart so it can increase atherosclerosis risk, 
increased cardiac contractility, increased car-
diac output and decreased systematic vascular 
resistance.34 
Based on result of the researches show 
that there are significant different between real 
cost of the hospital and package cost INA-CBG, 
total real cost from 92 hospital respondent is 
IDR 51.472.900,00 with average IDR 559.488,04 
for each patient and total cost covered by the 
BPJS through package cost INA-CBG with code Q-
5-44-0 as much as IDR 185.500,00 for each 
patient and total cost INA-CBG is IDR 
17.066.000,00. The results showed that the 
laboratory costs were 85% of the total real 
hospital costs, so the INA-CBG package was 
unable to cover all components of the cost of 
treatment hyperthyroidism. This resulted in 
losses for the hospital of (-) IDR 34.406.900,00 
and an average of (-) IDR 373.988,04 every 
patient. The results of this study are different 
from previous studies regarding hyperthyroid 
disease, because this study focuses on the 
component of the cost of treatment hyper-
thyroidism with a comparative study method. 
This research is a development of 
previous research conducted by Dian Ayu 
Juwita, Suhatri and Risa Hestia.17 The results of 
this study also contain useful implications as 
input in the future for the government as the 
BPJS organizer to further calculate the cost 




benchmark to cover all treatment costs and 
service claims in health facilities, especially 
hospitals. In addition, this study can contribute 
to the empirical literature regarding the cost-
effectiveness of direct treatment and its 
comparison with the cost of the INA-CBG 
package that has not been carried out in 
previous studies. The limitation in this study is 
that the total of samples is still insufficient 
because this study was only conducted in one 
hospital. 
CONCLUSION AND RECOMMENDATION 
The INA-CBG package does not cover all 
components of hospital costs for hyperthyroid 
disease, causing hospital losses with a difference 
of (-) IDR 34.406.900,00 and an average of (-) 
IDR 373.988,04 every patient. So it is 
recommended of Hasanuddin University 
Hospital Makassar need to ask the government 
to adjust the INA-CBG by requesting an upgrade 
to the standard of the INA-CBG package to be 
able to reimburse hospital claims for outpatient 
treatment of hyperthyroid disease. 
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